Pure Biologics Spólka Akcyjna (PUR) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.011x

Based on the latest financial reports, Pure Biologics Spólka Akcyjna (PUR) has a cash flow conversion efficiency ratio of 0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-216.00K ≈ $-59.45K USD) by net assets (zł-19.39 Million ≈ $-5.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Pure Biologics Spólka Akcyjna to measure how much of total assets are equity-financed.

Pure Biologics Spólka Akcyjna - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Pure Biologics Spólka Akcyjna's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Pure Biologics Spólka Akcyjna earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

Pure Biologics Spólka Akcyjna Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Pure Biologics Spólka Akcyjna ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Indo Straits Tbk JK:PTIS	0.048x
Quoin Pharmaceuticals Ltd DRC NASDAQ:QNRX	-0.555x
Paratech Company Limited KQ:033540	-0.044x
Winfarm PA:ALWF	0.152x
Harper Hygienics S.A. WAR:HRP	0.013x
Cambium Networks Corp NASDAQ:CMBM	0.113x
Batero Gold Corp V:BAT	-0.003x
Umpas Holding AS IS:UMPAS	-0.256x

Annual Cash Flow Conversion Efficiency for Pure Biologics Spólka Akcyjna (2016–2024)

The table below shows the annual cash flow conversion efficiency of Pure Biologics Spólka Akcyjna from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Pure Biologics Spólka Akcyjna worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	zł-13.12 Million ≈ $-3.61 Million	zł-10.83 Million ≈ $-2.98 Million	0.826x	+106.72%
2023-12-31	zł1.89 Million ≈ $520.98K	zł-23.26 Million ≈ $-6.40 Million	-12.288x	-1193.16%
2022-12-31	zł18.30 Million ≈ $5.04 Million	zł-17.39 Million ≈ $-4.79 Million	-0.950x	-56.11%
2021-12-31	zł39.49 Million ≈ $10.87 Million	zł-24.04 Million ≈ $-6.61 Million	-0.609x	-229.88%
2020-12-31	zł-2.89 Million ≈ $-794.54K	zł-1.35 Million ≈ $-372.37K	0.469x	-36.63%
2019-12-31	zł7.21 Million ≈ $1.99 Million	zł5.33 Million ≈ $1.47 Million	0.740x	+166.02%
2018-12-31	zł2.22 Million ≈ $611.22K	zł-2.49 Million ≈ $-684.71K	-1.120x	+91.75%
2017-12-31	zł209.77K ≈ $57.73K	zł-2.85 Million ≈ $-784.16K	-13.583x	-496.09%
2016-12-31	zł311.70K ≈ $85.78K	zł-710.24K ≈ $-195.47K	-2.279x	--

About Pure Biologics Spólka Akcyjna

WAR:PUR Poland Biotechnology

Market Cap

$8.76 Million

zł31.84 Million PLN

Market Cap Rank

#27386 Global

#297 in Poland

Share Price

zł2.81

Change (1 day)

+26.01%

52-Week Range

zł1.42 - zł7.70

All Time High

zł142.00